FOLH1 and prostate carcinoma: This study demonstrates that the combination of the BET inhibitor AZD5153 with the PSMA-targeted alpha-emitting radioligand [212Pb]Pb-AB001 enhances therapeutic efficacy in prostate cancer models, with synergistic effects observed specifically in 3D spheroids.